Development, validation and comparison of two nomograms predicting prostate cancer at initial 12-core biopsy.

about

Development, validation and comparison of two nomograms predicting prostate cancer at initial 12-core biopsy.

Item

http://www.wikidata.org/entity/Q40181136

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Development, validation and co ...... cer at initial 12-core biopsy.

@en

type

Item

label

Development, validation and co ...... cer at initial 12-core biopsy.

@en

prefLabel

Development, validation and co ...... cer at initial 12-core biopsy.

@en

P1476

Development, validation and co ...... cer at initial 12-core biopsy.

@en

P2093

Amir Kasaeian

http://www.w3.org/2001/XMLSchema#string

Mansour Jamali Zavarehei

http://www.w3.org/2001/XMLSchema#string

Mohammad Reza Eshraghian

http://www.w3.org/2001/XMLSchema#string

Mohammad Reza Nowroozi

http://www.w3.org/2001/XMLSchema#string

Mohsen Ayati

http://www.w3.org/2001/XMLSchema#string

Shahab Amini

http://www.w3.org/2001/XMLSchema#string

P2860

Landmarks in prostate cancer diagnosis: the biomarkers

The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.

External validation and head-to-head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets.

Changing demography of prostate cancer in Asia.

A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer.

Prostate cancer: an emerging threat to the health of aging men in Asia

Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases.

Landmarks in prostate cancer screening.

Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL.

Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination.

P304

e289-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJCO.12186

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261254379

http://www.w3.org/2001/XMLSchema#string

P698

24684767

http://www.w3.org/2001/XMLSchema#string